Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/7375
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFitria, Najmiatul-
dc.contributor.authorSyaputri, Yolanda Zazna-
dc.contributor.authorAkram, Muhammad-
dc.contributor.authorNasif, Hansen-
dc.contributor.authorMardatillah-
dc.date.accessioned2024-11-06T08:21:41Z-
dc.date.available2024-11-06T08:21:41Z-
dc.date.issued2024-04-
dc.identifier.citationOriginal Articleen_US
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/7375-
dc.description.abstractIntroduction: The combination of amlodipine and candesartan can have a better effect, although the costeffectiveness analysis was not yet determined. This research aimed to establish the Incremental Cost-Effectiveness Ratio (ICER) value among outpatients with hypertension who used amlodipine-candesartan. Method: This research was a descriptive study that retrospectively gathered data from medical records . Medical records data focused on information for hypertensive patients at Universitas Andalas Hospital in 2021. This study compared the standard treatment involving amlodipine-candesartan and sole amlodipine, next to calculate the ICER using cost-effectiveness analysis. Results: Out of the total population of 284, as many as 73 patients were involved in this study. Among these, 21 patients (28.77%) were treated with amlodipine alone, while 52 (71.23%) received an amlodipine-candesartan combination. The Incremental Cost-Effectiveness Ratio (ICER) for reducing systolic blood pressure was IDR 74,738.10 per one mmHg decrease in the northeast quadrant of the cost-effectiveness chart. The ICER for lowering diastolic blood pressure was IDR 205,918.24 per one mmHg decrease in the northeast quadrant on the cost-effectiveness chart. Conclusion: The cost of the amlodipine-candesartan combination yields superior effects; however, warranting a probabilistic sensitivity analysis to determine its ICER robustness is essential for its effective implementation.en_US
dc.language.isoen_USen_US
dc.publisherJurnal Sains Farmasi & Klinisen_US
dc.subjectamlodipineen_US
dc.subjectantihypertensionen_US
dc.subjectcandesartanen_US
dc.subjectcost-effectiveness analysisen_US
dc.subjectincremental cost-effectiveness ratioen_US
dc.titleAmlodipine-Candesartan Combination: A Cost-Effective Strategy for Successful Therapy of Hypertensionen_US
dc.typeArticleen_US
Appears in Collections:VOL 11 NO 1 2024

Files in This Item:
File Description SizeFormat 
32-38.pdf564.74 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.